

RTOG

Radiation Therapy Oncology Group

a leader in defining more effective cancer therapies



The Newsletter of the Radiation Therapy Oncology Group

No. 36, September 2004

In This Issue

Scientific Session	2
Tobacco Settlement Funded Research	2
Robert Ginsberg Surgical Oncology Award	2
Simon Kramer New Investigator Award	2
Corporate Sponsors	2
News Items	3
People in the News	
Web-Based Patient Entry Mandatory	
New Members	
RTOG Disease Site Teams	3
New Protocols	4
RTOG Endorsed Studies	4
RT QA Department	5
New Phantoms Available	
Farewell to Bernadine Dunning	
CTSU Update	6
RTOG Symposium - June 2004	7
RTOG ASTRO 2004 Presentations	8
RTOG Publications January - August	9-10
RTOG 2003 Top Accruing Institutions	11
Active Protocol List	12
Randomization Desk Hours	12
Future Meeting Dates	12



Members of the RTOG Head & Neck Study Team in their new common area.

New Offices New Disease Site Teams @ HQ



The Philadelphia Office of the American College of Radiology (ACR), which houses the RTOG, moved to new offices on July 12, 2004. The new space, which was custom configured for the ACR, comprises the entire 16th floor and part of the 17th floor of a 40 story building in downtown Philadelphia. It features state-of-the-art meeting and conference facilities that will enable staff to partake in video conferences and will enhance the acoustics of regular conference calls. RTOG's office space was configured to support the new RTOG disease site team structure (see page 3 for more details on the disease site team structure.) Each team has its own area in the office. In addition to the

standard offices and cubicles there is open space with modular tables and chairs that can easily be pulled together for impromptu meetings. There are also a number of private meeting rooms that can be reserved when teams need to be away from the everyday hustle and bustle.

The new office is easily accessible by the regional rail and commuter trains. There is also a parking garage on the first six floors of the building. The new address for RTOG Headquarters and the Statistical Unit is: 1818 Market Street, Suite 1600, Philadelphia, PA 19103. The phone numbers remain the same.

www.rtog.org

Committee minutes from RTOG meetings are available on the RTOG Web site. The minutes are also published in the semi-annual meeting book. Check the Web site (www.rtog.org) for up-to-the minute press releases, phone lists, protocols, protocol amendments, active study lists, protocol forms, and telephone lists.

The Scientific Session at the RTOG 2004 Summer Semi-Annual Meeting featured research supported by the Pennsylvania Department of Health Tobacco Settlement Fund as well as three presentations of recent RTOG research, and the Simon Kramer New Investigator Award presentation.

Tobacco Settlement Fund Support Research

- Alan Pollack, M.D., Ph.D., Fox Chase Cancer Center. Prostate Cancer Markers of Outcome After Radiotherapy
- Randy Burd, M.D., Thomas Jefferson University. New Drug Development.
- Deborah Bruner-Watkins, RN, Ph.D., Fox Chase Cancer Center. Outcomes Associated with Cancer Therapy in Special Populations and Ethnic Minorities at High-Risk for Poor Outcomes: Focus on Head & Neck Cancers.

Simon Kramer New Investigator Award

Arnab Chakravarti, M.D., Harvard Medical School

Enhancing Radiation Response of Human Glioblastomas through Molecular Targeting Strategies.



Robert Ginsberg Surgical Oncology Award

Geoffrey Porter, M.D., Dalhousie University

Presentations on Recent RTOG Research

- Edward Shaw, M.D., Wake Forest University. *An Intergroup Randomized Controlled Clinical Trial (RCT) of Chemotherapy plus Radiotherapy (RT) versus RT alone for Pure and Mixed Anaplastic Oligodendroglioma: Initial Report of RTOG 94-02. Proc Am Soc Clin Oncol (ASCO), New Orleans, LA, J Clin Oncol, pg. 107, Abs. #1500, 2004.* Cairncross, G., Seiferheld, W., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., Buckner, J., Fink, K., Souhami, L. and Curran Jr, W.
- Beryl McCormick, M.D., Memorial Sloan-Kettering. *A Randomized Comparison of Lumpectomy plus Tamoxifen with and without Irradiation in Women 70 Years of Age or Older who Have Clinical Stage I, Estrogen Receptor Positive Carcinoma of the Breast. New Eng J Med, ACCEPTED.* Hughes, K., Schnaper, L., Berry, D., Cirrincione, C., McCormick, B., Shank, B., Wheeler, J., Champion, L., Smith, T. J., Smith, B. L., Shapiro, C., Muss, H., Winer, E., Hudis, C., Wood, W., Sugarbaker, D., Henderson, C. and Norton, L.
- W. Robert Lee, M.D., Wake Forest University. *A Phase II Study of External Beam Radiation Therapy Combined With Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate: Preliminary Results of RTOG P-0019. Proc Am Soc Clin Oncol (ASCO), New Orleans, LA, J Clin Oncol, pg. 397, Abs. #4568, 2004.* Lee, W., DeSilvio, M., Lawton, C., Gillin, M., Morton, G., Firat, S., Baikadi, M., Kuettel, M., Greven, K. and Sandler, H.

Corporate Support

RTOG would like to thank the Corporate Sponsors and Contributors for their generous and unrestricted support for the educational aspects of our Semi-Annual Meeting.

Corporate Sponsors



Corporate Contributors

Amgen	Ortho Biotech
AstraZeneca	Pharmacyclics
Elekta, Inc.	Roche Laboratories
IMPAC Medical Systems	Sanofi-Synthelabo, Inc.
Novartis Oncology	

People in the News

Ross A. Abrams, M.D., Vice Chair for Disease Sites, has moved. His new contact information is: Professor and Chairman, Radiation Oncology, Rush University Medical Center, Women's Board Cancer Treatment Center, 520 S. Paulina, Chicago, IL 60612, (312) 942-7775, Ross_A_Abrams@rush.edu.

Robert Timmerman, M.D. has moved His new contact information is: Professor & Vice Chairman, Radiation Oncology, Univ. of Texas Southwestern, 5801 Forrest Park Road, Dallas, TX 75390, (214) 645-7637, robert.timmerman@utsouthwestern.edu.

Web-Based Registration Mandatory

Beginning January 1, 2005, all RTOG studies available for web registration from the RTOG web site will require mandatory web registration. Protocols that have special drug ordering procedures or pathology eligibility requirements will remain as dial-in registrations. A current list of these studies is provided below and is available on the web site at <http://www.rtog.org/members/webreg.html>.

Please note - all protocols will be amended to reflect this change, but may not be completed by the deadline. Web registration for protocols not amended will still be mandatory.

Starting immediately - all new protocols activated will have mandatory web registration, unless otherwise specified. Institutions who call to register patients to these studies will be directed to the web site.

0017	Lung: Gemcitabine
0022	Head & Neck: IMRT
0113	Esophagus
0126	Prostate: 3D/IMRT
0129	Head & Neck: Stage III/IV
0132	GI Tumors
0212	Lung: PCI Small Cell Lung
0213	Lung Celebrex
0214	Lung: PCI NSCLC
0225	Nasopharynx
0227	Lymphoma
0232	Prostate: Brachytherapy
0233	Bladder Preservation
0234	H&N: C225
0236*	Lung: Stereotactic Body RT (SBRT)
0239	SCLC: Higher Dose RT + Chemo
0241	Lung: Irinotecan, Cis., RT for SCLC
0244	Salivary Gland Transfer
0246	Esophagus: Surgical Salvage
0321*	Prostate: High Dose Brachy
0324	Lung: C225 Stage IIIA/B
9804	Breast: RT & Tamoxifen
9811	Anal Canal

*Web registration mandatory now for this study

New Members

RTOG welcomes 17 new institutions and their Principal Investigators since the beginning of the year!

New CCOPS:

Mount Sinai Hospital MBCCOP - Vivian D. Griffin, MD

New Affiliates:

Thedacare Cancer Institute - Robert Belgam, MD
 Dickinson County Healthcare Sys. - Nelson L. Adamson, MD
 Faxton - St. Lukes Healthcare - Faina Sherman, MD
 Presbyterian Intercommunity Hos. - William Kurohara, MD
 Aultman Hospital - Douglas R. Keyser, MD
 Parkview Cancer Center/Parkview Hospital - Tony Lee, MD
 Cancer Institute of Cape Girardeau - Tapan Roy, MD
 Johnson City Medical Center - James Blom, MD
 Cancer Care Manitoba Foundation - Ahmet Leylek, MD
 Cape Fear Valley Health System, Inc. - Thomas Walden, MD
 Wake Radiology Oncology Services, PLLC - Scott Sailer, MD
 Rochester General Hospital - William B. Casey, MD
 Cooper Health System - Steven J. DiBiase, MD
 Bethesda Memorial Hospital - James T. Parsons, MD
 Scottsdale Rad. Onc. Ctrs., Shea Center - Farley Yang, MD
 Univ. of Texas Southwest Med. School - L. Chinsoo Cho, MD

New Disease Site Teams @ HQ

RTOG headquarters staff have been divided into disease site teams. There are currently six teams: CNS, CCOP, Breast/Gynecology/GI, Head & Neck/Sarcoma, Genitourinary, and Lung. Each team is composed of a Senior Statistician (Team Leader), a Statistician, a Primary Data Manager, a Secondary Data Manager, a Radiation Therapy Quality Assurance Dosimetrist, a Protocol Associate, and a Data Support Clerk. The new RTOG office space has been configured so that team members are grouped into distinct areas with common space to facilitate ad hoc team meetings.

continued on the next page



Lung Team members, Suzanne Swann, Linda Walters, Brian Berkey, and Joanne Ley meet in the team common area.

New Studies

Lung Cancer – RTOG 0236, “A Phase II Trial of Stereotactic Body RT (SBRT) in the Treatment of Patients with Medically Inoperable Stage I/II Non-Small Cell Lung Cancer.” Activated May 26, 2004. PI: Robert D. Timmerman, M.D., UT Southwestern, 214-645-7637, robert.timmerman@utsouthwestern.edu. Required sample size: 52 patients with T1, T2 (≤ 5 cm), T3 (≤ 5 cm), N0, M0 medically inoperable NSCLC.

Head & Neck Cancer – RTOG 0234, “A Phase II Randomized Trial of Surgery Followed by Chemoradiotherapy Plus C225 (Cetuximab) for Advanced Squamous Cell Carcinoma of the Head & Neck.” Activated April 20, 2004. PI: Paul M. Harari, M.D., Univ. of Wisconsin-Madison, 608-263-8500, harari@humonc.wisc.edu. Required sample size: 230 patients with pathologic stage III or IV (preoperative clinical stage may be I-IV if nodes are not appreciated) squamous carcinoma of the head & neck following gross total resection and requiring postop XRT for high-risk features.

Prostate Cancer – RTOG 0321, “Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam RT for Adenocarcinoma of the Prostate.” Activated July 30, 2004. PI: I-Chow Hsu, M.D., UCSF, 415-353-7175, hsu@radonc17.ucsf.edu. Required sample size: 110 men with histologically confirmed, adenocarcinoma of the prostate with one of the following combinations: clinical stage T1c - T2c, Gleason score 2-6 & PSA > 10 but ≤ 20 ; clinical stage T3a, T3b, Gleason score 2-6 & PSA ≤ 20 ; or clinical stage T1c - T3b, Gleason score 7-10 & PSA ≤ 20 .

Sarcoma – RTOG 0330, “A Pilot Phase II Study of Pre-Operative RT and Thalidomide (IND 48832; NSC 66847) for Low Grade Primary Soft Tissue Sarcoma or Pre-Operative Mard/Thalidomide/RT for High/ Intermediate Grade Primary Soft Tissue Sarcoma of the Extremity or Body Wall.” Activated June 17, 2004. PI: Burton L. Eisenberg, M.D., NCCC, DHMC, 603-653-2613, burton.l.eisenberg@dartmouth.edu. Required sample size: 44 patients with a primary T2a or T2b soft tissue sarcoma.

Disease Site Teams continued from page 3

The teams meet formally once per week and informally as needed. Topics discussed during team meetings are varied. For ongoing studies any or all of the following topics may be addressed:

- The status and prioritization of data review and entry
- The status of modality reviews
- Validations and surveillance program implementation
- Protocol revisions
- Form changes
- Upcoming analyses

The teams review all developing studies in their disease sites. Particular attention is directed to the study objectives, eligibility criteria, assessments and data collection, and adverse event reporting. Each protocol must contain criteria for modality reviews and the timing of those reviews. Outcomes and translational research endpoints must have received approval in order for those endpoints to become part of the protocol. For each developing study the team works collectively to address the following:

- Form design and implementation
- Validation and surveillance program rules and implementation
- Contract issues
- Modality review parameters and timing.

The team implementation is now in its ninth month. There has been a great deal of positive feedback from team members. We hope this configuration will enable the RTOG to continue to even greater productivity.

Other Group Studies Endorsed by RTOG

RTOG endorsed studies are offered either through the Cancer Trials Support Unit (www.ctsu.org) or a sponsoring facility. RTOG awards case credit for patients entered on these studies.

Breast

NCIC-MA.20: Phase III Study of Regional Radiation Therapy in Early Breast. Register through CTSU.

Lung

T99-0046: Phase III Study for NSCLC Stage III (IIIA Inoperable and IIIB): ChemoRT (Taxol-Carbo or Navelbine-Cisplatin followed by ChemoRT) with and without Neovastat,[®] (RTOG 0270). Register through the MD Anderson Cancer Center (713)792-8515.

NCIC BR.19: A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer. Register through CTSU.

Pancreas

E4201: Phase III Study of Gemcitabine in Combination with RT versus Gemcitabine Alone for Localized, Unresectable Pancreatic Cancer Patients. Register through CTSU.

Prostate

MDA-3410: Phase III Trial of Consolidation Therapy w/without Strontium-89 Following Induction Chemo in Androgen-Independent Prostate Cancer. Register through CTSU.

JPR.7:NCIC CTG: Phase III Trial of Intermittent vs Continuous Androgen Suppression for Prostate Cancer Patients with PSA Progression and No Distant Metastases Following RT. Register through CTSU.

RPC Phantoms are Available for Credentialing

by Geoffrey S. Ibbott, Ph.D., Director, Radiological Physics Center, UT M.D. Anderson Cancer Center

Several clinical trials currently offered by the RTOG allow, or are investigating, the use of IMRT. Guidelines published by the NCI advise that institutions be credentialed before they participate in these protocols. The Radiological Physics Center (RPC) provides a family of anthropomorphic phantoms that are used by the RTOG as part of the credentialing requirements. The phantoms are shipped to an institution, which conducts imaging procedures, prepares a treatment plan, and delivers the plan to the phantom. The phantom is then returned to the RPC where the dosimeters are removed and analyzed.

To meet the demand for credentialing, the RPC has built several copies of each phantom model. At the moment, head & neck and pelvis phantoms are available immediately to institutions needing them for credentialing. There is a short waiting list for the thorax phantom, but institutions should not have to wait more than several weeks, barring an unexpected increase in demand.

To help us minimize the wait for phantoms, the RPC asks that institutions carefully review the requirements for credentialing and the specific procedures for obtaining and irradiating the phantoms. Institutions are requested to anticipate the effort required and plan to return the phantom after no more than one week.

In addition, institutions are reminded that credentialing for most of these protocols requires that several requirements for electronic data submission be satisfied. An account must be obtained from the Image-Guided Therapy QA Center (ITC) in St. Louis, and a "dry-run" treatment plan (of a patient planned in compliance with the protocol) must be submitted. Finally, the RPC expects that institutions will submit the treatment plan performed for the phantom electronically to the ITC. Doing so facilitates our evaluation of the dosimeters.

The procedures for electronic submission, and evaluation of the "dry-run" can be performed prior to, or concurrently with the phantom irradiation. However, institutions are discouraged from requesting the phantom if they anticipate difficulties or delays with meeting the electronic submission requirements.

To request a phantom for credentialing, please contact the RPC at 713-745-8989 or visit our web site at <http://rpc.mdanderson.org/rpc>. Click on Credentialing, then RTOG, and select the protocol of interest.

Fond Farewell to Bernadine Dunning

By Elizabeth Martin, Director RTOG RT Quality Assurance



Bernadine Dunning, a dosimetrist in the RTOG RT Quality Assurance Department, has taken a new position on another project in the Philadelphia office of the American College of Radiology (ACR) and is no longer with the RTOG. Bernadine, who started working for RTOG in 1993, transferred to another project within ACR in May of 2004 and she is now a Project Specialist in the Diagnostic Imaging Administration Department of the American College of Radiology Imaging Network (ACRIN).


Bernadine held a number of positions before coming to RTOG including working in hospitals as a radiologic technologist, a radiation therapist, and a chief therapist and a dosimetrist. During her time with RTOG, she managed the RTQA for multiple studies in multiple disease sites resulting in changes for patients in how their cancer is treated.

Bernadine had the great opportunity to participate as an RTOG representative in the "Bad Blood" conference, a cooperative group event in Tuskegee, Alabama. This meeting was held to address the problems related to recruitment of minorities and "special populations" into clinical trials. This was living history for Bernadine as she had previously done research on the Tuskegee trial.

During the ten years that Bernadine was with the RTOG she participated in the Advanced Technology Consortium and served as the RTQA dosimetrist for the Image Guided Therapy Center. In this role, she has worked with the remote review tools and played a role in improving them. Her work included reviewing the dose volume histograms on multiple studies as well as using the tool to remotely contour body structures for the prostate studies. Her presentations on RT quality assurance for the Research Associate Orientation and Round Table discussions held at the RTOG Semi-Annual Meetings were extremely informative and always well received.

Working together with the RTOG staff and investigators to improve the lives of cancer patients has been a wonderful experience for Bernadine and she has enjoyed being a part of an organization that makes a real difference in people's lives.

Please join me in extending warm thanks to Bernadine for her dedication and commitment to the RTOG and wishing her much success in her new position.



Cancer Trials Support Unit Update

Congratulations to Abbot- Northwest Metro-Minnesota CCOP which has enrolled the most patients (19) via the CTSU out of all the RTOG sites!

RTOG Lead Studies - Target/Current/CTSU Accruals and Site Registrations through the CTSU (as of 8/31/04)

Protocol	Target Accrual	Current Accrual	CTSU Accrual	Sites Registered
RTOG-0214	1058	77	5	188
RTOG-0232	1520	54	0	3
RTOG-98-04	1790	458	15	122
RTOG-99-02	1440	397	3	80
RTOG-P-0014	1050	14	2	97

The above chart illustrates the target accrual for the study, the current accrual for the study, the CTSU accrual for the study, and the number of approved site registrations for all RTOG trials on the CTSU menu as of 8/31/04.

RTOG Endorsed Studies-Target/Current/CTSU Accruals and RTOG Enrollments through the CTSU (as of 6/22/04)

Protocol	Target Accrual	Current Accrual	CTSU Accrual	RTOG CTSU Accrual
ECOG-4201	332	22	4	1
MDA-3410	680	38	13	0
NCIC CTG JPR.7	1340	1033	35	10
NCIC CTG BR.19	1242	333	272	15
NCIC CTG MA.20	1822	950	21	12

The above chart illustrates the target accrual for the study, the current accrual for the study, the CTSU accrual for the study, and the RTOG enrollments through the CTSU as of 6/22/04 for all RTOG endorsed studies.

Cancer Trials Support Unit Remote Data Capture Project

The Cancer Trials Support Unit (CTSU), in conjunction with the North Central Cancer Treatment Group (NCCTG), has initiated a pilot project to test the feasibility and advantages of centralized data collection within the Cooperative Group environment. This project will utilize Remote Data Capture (RDC), which permits sites to enter patient-level data into an Oracle Clinical database over the Internet. RDC is also used to notify the sites of discrepant data and provide tools for data correction online at the point of entry. The CTSU initiated training programs for NCCTG sites at the group meetings and has been and will continue to conduct classes on the RDC system.

The CTSU has initiated this project with the NCCTG's N0147 study. This study is a randomized phase III trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) plus 5-Flourouracil (5-FU)/ Leucovorin (CF) after curative resection for patients with stage III Colon Cancer. The protocol was activated on February 10, 2004 and is expected to enroll 3,750 patients.

All NCCTG sites that participate in N0147 will be required to register their site, enroll patients, and submit data (using RDC) via the CTSU (whereas typically an NCCTG site would enroll patients and submit data directly with NCCTG). Non-NCCTG sites who wish to participate in N0147 will do

so through the CTSU and are not required to submit data via RDC, though they may do so upon completion of training in the use of the software. Non-NCCTG sites are encouraged to participate. Training provides qualification for any of the other protocols available through RDC.

The CTSU has developed the N0147 study database in Oracle Clinical in close collaboration with NCCTG. Data entered into the CTSU database will be transmitted electronically to the NCCTG on a regular and frequent basis using the Clinical Data Transfer System developed using XML technology. The NCCTG will be responsible for statistical quality control, medical review, and interim and final analysis. Timeliness and accuracy of data submission will be monitored by the CTSU with data quality assurance reports being provided on a regular basis.

All N0147 site registrations will be done through the CTSU/RSS (Regulatory Support System). Registration will require the use of the CTSU IRB Certification Form, IRB Regulatory Approval Transmittal Sheet, and IRB-approved consent form. Sites can check the status of their site registration by visiting the 'Resources' tab on the members' side of the CTSU web site at <http://members.ctsu.org>.

For more information regarding RDC and CTSU, please contact the CTSU Help Desk at 1-888-823-5923 or CTSUContact@westat.com

Anti-Angiogenic Therapy: Maximizing Therapeutic Gain

Symposium Co-Chairs

Adam P. Dicker, MD, PhD

Director- Division of Experimental Radiation
Oncology
Associate Professor
Jefferson Medical College of
Thomas Jefferson University

Michael O'Reilly, MD

Assistant Professor Radiation Oncology
Assistant Professor of Cancer Biology
University of Texas
M.D. Anderson Cancer Center

Invited Faculty

Christopher G. Willett, MD

Professor & Chair
Department of Radiation Oncology
Duke University Medical Center

Roy Herbst, MD, PhD

Associate Professor Medicine
Associate Professor of Cancer Biology
University of Texas
M.D. Anderson Cancer Center

Raghu Kalluri, PhD

Director, Center for Matrix Biology
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard University

Giannoula Klement, MD, FRCP(C)

Pediatric Neuro-Oncology
Dana-Farber Cancer Institute
& Vascular Anomalies Clinic
Children's Hospital Boston
Harvard Medical School

Zvi Fuks, MD

Deputy Physician-in-Chief, Planning
Alfred P. Sloan Chair
Memorial Sloan Kettering Cancer Center

Cheryl Baker, PhD

Assistant Professor of Cancer Biology
University of Texas
M.D. Anderson Cancer Center

George D. Yancopoulos, MD, PhD

Executive Vice President
Regeneron Pharmaceuticals, Inc.

Steven Libutti, MD

Senior Investigator
Surgery Branch
National Cancer Institute

Kevin Camphausen, MD

Radiation Oncology Branch
National Cancer Institute

The goals of the symposium were to:

- Review the role of angiogenesis in normal tissue biology and cancer cell biology.
- Describe the mechanism of action in tumor-growth inhibition of selective antiangiogenic inhibitors.
- Discuss the effects of antiangiogenic inhibitors on preclinical tumor models alone and in combination with cytotoxic chemotherapy and radiation therapy.
- Discuss the issues regarding clinical trial design using novel agents.
- Discuss the results of clinical trials using inhibitors of angiogenesis alone or in combination with radiation or chemotherapy.

PLENARY SESSION PRESENTATIONS

HEAD & NECK CANCER

RTOG 9903: Preliminary Report on Definitive Radiotherapy \pm Erythropoietin for Squamous Cell Carcinoma of the Head and Neck.

Machtay, M., Pajak, T., Suntharalingam, M., Hershock, D., Stripp, D. C., Cmelak, A., Shenouda, G., Schulsinger, A. and Fu, K.

PROSTATE CANCER

PROG 9509: Randomized Trial of Conventional Dose (70.2GyE) and High-Dose (79.2GyE) Conformal Radiation in Early Stage Prostate Adenocarcinoma.

Zietman, A., DeSilvio, M., Slater, J., Rossi, C., Yonemoto, L., Slater, J., Berkey, B., Adams, J. and Shipley, W.

ORAL & POSTER PRESENTATIONS

BRAIN TUMORS

RTOG 9402: Radiotherapy Alone vs Intensive Procarbazine-CCNU-Vincristine Chemotherapy Followed by Radiotherapy for Anaplastic Oligodendroglioma and Mixed Oligo-Astrocytoma – *Shaw, E., Seiferheld, W., Cairncross, G., Jenkins, R., Scheithauer, B., Brachman, D., Buckner, J., Fink, K., Souhami, L. and Curran Jr, W.*

RTOG 9803: Phase I/II Conformal Three-Dimensional Radiotherapy Dose Escalation Study for Patients with Supratentorial Glioblastoma Multiforme – *Werner-Wasik, M., Seiferheld, W., Michalski, J., Gilbert, M., Purdy, J., Simpson, J., Kresi, J., Curran Jr, W., Diaz, A. and Mehta, M.*

CERVICAL CANCER

RTOG C-0128: Feasibility of RNA Collection for Micro-Array Gene Expression Analysis of Cervical Carcinoma Treatment – *Gaffney, D., Winter, K., Fuhrman, C., Flinner, R., Greven, K., Ryu, J., Forbes, A., Kerlin, K., Nicholas, R. and Zempolich, K.*

PROSTATE CANCER

RTOG 9805: Phase II Trial of Transrectal Ultrasound Guided Permanent Radioactive Implantation for Definitive Management of Localized Prostate Adenocarcinoma – *Lawton, C., DeSilvio, M., Lee, W., Gomella, D., Grignon, D., Gillin, M., Morton, G., Pisansky, T. and Sandler, H.*

RTOG 9406: Clinical Outcome of Patients Treated with 3D Conformal Radiotherapy for Prostate Cancer. – *Michalski, J., Winter, K., Roach III, M., Markoe, A., Sandler, H., Ryu, J., Parliament, M., Purdy, J., Valicenti, R. and Cox, J.*

RTOG 9413: Progression Free Survival after Whole-Pelvic vs "Mini-Pelvic" or Prostate-Only RT: A Subset Analysis of a Phase III Trial Using Neoadjuvant & Concurrent Chemo – *Roach, M., DeSilvio, M., Thomas Jr., C., Valicenti, R., Asbell, S., Lawton, C. and Shipley, W.*

RTOG 8610: Influence of the Number of CAG Repeats on Local Control – *Abdel-Wahab, M., Berkey, B., Krishan, A., O'Brien, T., Hammond, E., Roach III, M., Lawton, C., Pilepich, M., Markoe, A. and Pollack, A.*

RTOG 8610: MDM2 as a Predictor of Prostate Cancer Outcome – *Khor, L., DeSilvio, M., Al-Saleem, T., Hammond, E., Sause, W., Pilepich, M., Okunieff, P., Sandler, H. and Pollack, A.*

HEAD AND NECK CANCER

RTOG 9003 & 9111: Quality of Life Variables Influence Local Regional Control in RTOG Head & Neck Trials – *Movsas, B., Konski, A., Pajak, T., Coyne, J., Gwede, C., Garden, A., Spencer, S., Jones, C. and Watkins Bruner, D.*

RTOG H-0024: Early Postoperative Paclitaxel Followed by Paclitaxel and Cisplatin Concurrent with Radiotherapy is Well Tolerated by Patients with Resected, High-Risk Squamous Cell Carcinoma of the Head and Neck – *Rosenthal, D., Harris, J., Forastiere, A., Weber, R., Ridge, J., Myers, J., Garden, A., Kuettel, M., Sidhu, K., Schultz, C. and Ang, K. K.*

Comparison of Intra-Arterial Cisplatin and Radiotherapy to Other RTOG Regimens Using Standard or Accelerated Radiotherapy with or without Concurrent Chemotherapy in Patients with Stage IV-T4 Head and Neck Cancer – *Kumar, P., Harris, J., Garden, A., Fu, K., Robbins, K. T., Pajak, T. and Ang, K. K.*

ENDOMETRIAL CANCER

RTOG 9708: Adjuvant Postoperative Irradiation Combined with Cisplatin/Taxol Chemotherapy Following Surgery for Patients with High-Risk Endometrial Cancer – *Greven, K., Winter, K., Underhill, K., Fontanesi, J., Cooper, J. and Burke, T.*

METASTATIC CANCER

RTOG 9714: Can Physicians Accurately Predict Survival Time in Patients with Metastatic Cancer? *Hartsell, W., DeSilvio, M., Bruner, D., Scarantino, C., Ivker, R., Roach III, M., Suh, J., Seider, M., Movsas, B., Petersen, I. and Konski, A.*

RTOG 9714: Prospective Health-Related Quality of Life Valuations (Utilities) of 8 Gy in 1 Fraction vs 30 Gy in 10 Fractions for Palliation of Painful Bone Metastases – *Bruner, D., Winter, K., Hartsell, W., Konski, A., Curran Jr, W., Roach III, M., Doncals, D., Movsas, B., Lee, D. and Scarantino, C.*

RECTAL CANCER

RTOG 0012: Randomized Phase II Study of Neoadjuvant Chemoradiation for Distal Rectal Cancer – *Mohiuddin, M., Winter, K., Mitchell, E., Hanna, N., Yuen, A., Nicholas, C., Share, R., Hayostek, C. and Willet, C.*

RTOG Publications January - August 2004

Below is a listing of RTOG Publications that were published during the first eight months of 2004. For additions or corrections to this list please contact Lisa Morabito at Imorabito@phila.acr.org or (215) 574-3163.

BRAIN TUMORS

Andrews, D., Scott, C., Sperduto, P., Flanders, A., Gaspar, L., Schell, M., Werner-Wasik, M., Demas, W., Ryu, J., Bahary, J.-P., Souhami, L., Rotman, M., Mehta, M. and Curran Jr., W.: Whole Brain Radiation Therapy With Or Without Stereotactic Radiosurgery Boost for Patients With One to Three Brain Metastases: Phase III Results of the RTOG 9508 Randomized Trial. *Lancet*, 363 (9422):1665-1672, 2004.

Brat, D., Seiferheld, W., Perry, A., Hammond, E., Murray, K., Schulsinger, A., Mehta, M. and Curran Jr., W.: Analysis of 1p, 19q, 9p, and 10q as Prognostic Markers for High-Grade Astrocytomas Using Fluorescence in situ hybridization on Tissue Microarrays from Radiation Therapy Oncology Group trials. *Neuro-Oncol*, 6 (2):96-103, 2004.

Brown, P., Buckner, J., O'Fallon, J., Iturria, N., Brown, C., O'Neill, B., Scheithauer, B., Dinapoli, R., Arusell, R., Abrams, R., Curran Jr, W. and Shaw, E.: Adult Patients with Supratentorial Pilocytic Astrocytomas: A Prospective Multicenter Clinical Trial. *Int J Radiat Onco Biol Phys*, 58 (4):1153-1160, 2004.

Brown, P., Buckner, J., O'Fallon, J., Iturria, N., O'Neill, B., Brown, C., Scheithauer, B., Dinapoli, R., Arusell, R., Curran Jr, W., Abrams, R. and Shaw, E.: Importance of Baseline Mini-Mental State Examination as a Prognostic Factor for Patients with Low-Grade Glioma. *Int J Radiat Onco Biol Phys*, 59 (1):117-125, 2004.

Cairncross, G., Seiferheld, W., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., Buckner, J., Fink, K., Souhami, L. and Curran Jr, W.: An Intergroup Randomized Controlled Clinical Trial (RCT) of Chemotherapy plus Radiation (RT) versus RT alone for Pure and Mixed Anaplastic Oligodendrogliomas: Initial Report of RTOG 94-02. *Proc Am Soc Clin Oncol (ASCO)*, New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. 107, Abs. #1500, 2004.

Chakravarti, A., Seiferheld, W., Robins, H., Guha, A., Brachman, D., Curran Jr, W., Choucair, A. and Mehta, M.: An Update of Phase I Data from RTOG 0211: A Phase I/II Clinical Study of Gefitinib + Radiation for Newly-Diagnosed Glioblastoma (GBM) Patients. *Proc Am Soc Clin Oncol (ASCO)*, New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. 124, Abs. #1571, 2004.

Chakravarti, A., Seiferheld, W., Robins, H., Guha, A., Brachman, D., Curran Jr., W., Choucair, A. and Mehta, M.: An Update of Phase I Data from RTOG 0211: A Phase I/II Clinical Study of ZD 1839 (Gefitinib/Iressa) + Radiation for Newly-Diagnosed Glioblastoma (GBM) Patients. *Am Assoc for Cancer Res (AACR)*, Orlando, FL, *AACR Proceedings Booklet*, [March, 2004] pg. Abs. #LB-333, 2004.

Chang, S., Seiferheld, W., Curran Jr., W., Share, R., Atkins, J., Choucair, A., Kresl, J., Thoron, L., Cairncross, J. G., Gilbert, M., Bahary, J.-P., Dolinskas, C., Louis, D., Bushurnow, P., Buckner, J., Barger, G. and Mehta, M.: Phase I Study Pilot Arms of Radiotherapy and Carmustine with Temozolomide for Anaplastic Astrocytoma (Radiation Therapy Oncology Group 9813): Implications for Studies Testing Initial Treatment of Brain Tumors. *Int J Radiat Onco Biol Phys*, 59 (4):1122-1126, 2004.

Choucair, A., Seiferheld, W., Ford, C., Hansen, J., Dabbas, B., Schultz, C., Schulsinger, A., Mehta, M. and Curran Jr., W.: Long Term Survivors with Glioblastoma Multiforme (GBM) Treated on RTOG Protocols with Irradiation and Nitrosourea Have Higher Initial Expression of Ki-67. *Proc Am Soc Clin Oncol (ASCO)*, New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. 871, Abs. #9661, 2004.

Ford, C., Seiferheld, W., Choucair, A., Hansen, J., Dabbas, B., Schultz, C., Schulsinger, A., Mehta, M. and Curran Jr., W.: Evaluation of Expression of DNA Repair Molecules as a Prognostic Factor for Long-Term Survivors with Glioblastoma Multiforme (GBM) Treated on RTOG Protocols with Irradiation and Nitrosoureas. *Proc Am Soc Clin Oncol (ASCO)*, New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. 109, Abs. #1509, 2004.

Prados, M., Seiferheld, W., Sandler, H., Buckner, J., Phillips, T., Schultz, C., Urtasun, R., Davis, R., Gutin, P., Cascino, T., Greenberg, H. and Curran Jr., W.: Phase III Randomized Study of Radiotherapy plus Procarbazine, Lomustine, and Vincristine with or without BUdR for Treatment of Anaplastic Astrocytoma: Final Report of RTOG 94-04. *Int J Radiat Onco Biol Phys*, 58 (4):1147-1152, 2004.

Regine, W., Schmitt, F., Scott, C., Dearth, C., Patchell, R., Nichols Jr., R., Gore, E., Franklin III, R., Suh, J. and Mehta, M.: Feasibility of Neurocognitive Outcome Evaluations in Patients with Brain Metastases in a Multi-Institutional Cooperative Group Setting: Results of Radiation Therapy Oncology Group Trial BR-0018. *Int J Radiat Onco Biol Phys*, 58 (5):1346-1352, 2004.

Robins, H., Won, M., Schultz, C., Choucair, A., Brachman, D., Demas, W. and Mehta, M.: A Phase II Trial of Conventional Radiation Therapy (XRT) Plus High Dose Tamoxifen (TAM) for the Treatment of Supratentorial Glioblastoma Multiforme (GBM): RTOG Protocol BR-0021. *Proc Am Soc Clin Oncol (ASCO)*, New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. 114, Abs. #1529, 2004.

BREAST CANCER

Kuske, R. R., Winter, K., Arthur, D., Bolton, J. S., Rabinovitch, R., White, J., Hanson, W. and Wilenzick, R. M.: A Phase II Trial of Brachytherapy Alone Following Lumpectomy for Stage I or II Breast Cancer: Initial Outcomes of RTOG 95-17. *Proc Am Soc Clin Oncol (ASCO)*, New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. 18, Abs. #565, 2004.

GASTROINTESTINAL CANCER

Mitchell, E., Winter, K., Mohiuddin, M., Hanna, N., Yuen, A., Nicholas, C., Share, R., Hayostek, C. and Willet, C.: Randomized Phase II Trial of Preoperative Combined Modality Chemoradiation For Distal Rectal Cancer. *Proc Am Soc Clin Oncol (ASCO)*, New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. 254, Abs. #3535, 2004.

Rich, T., Harris, J., Abrams, R. A., Erickson, B., Doherty, M., Paradelo, J., Small Jr., W., Safran, H. and Wanebo, H.: Phase II Study of External Irradiation and Weekly Paclitaxel for Nonmetastatic, Unresectable Pancreatic Cancer: RTOG-98-12. *Am J Clin Oncol*, 27 (1):51-56, 2004.

Thomas Jr., C., Berkey, B., Minsky, B., Gaspar, L., Herskovic, A., Rich, T. and Gunderson, L.: Recursive Partitioning Analysis of Pretreatment Variables of 416 Patients with Locoregional Esophageal Cancer Treated with Definitive Concomitant Chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group Trials. *Int J Radiat Onco Biol Phys*, 58 (5):1405-1410, 2004.

GYNECOLOGICAL CANCER

Eifel, P., Winter, K., Morris, M., Levenback, C., Grigsby, P., Cooper, J., Rotman, M., Gershenson, D. and Mutch, D.: Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical Cancer: An Update of Radiation Therapy Oncology Group Trial (RTOG) 90-01. *J Clin Oncol*, 22 (5):872-880, 2004.

Greven, K., Winter, K., Underhill, K., Fontanesi, J., Cooper, J. and Burke, T.: Preliminary Analysis of RTOG 9708: Adjuvant Postoperative Radiotherapy Combined with Cisplatin/Paclitaxel Chemotherapy after Surgery for Patients with High-Risk Endometrial Cancer. *Int J Radiat Onco Biol Phys*, 59 (1):168-173, 2004.

HEAD AND NECK CANCER

Bernier, J., Domenge, C., Ozsahin, M., Matuszewska, K., Lefebvre, J., Greiner, R., Giralt, J., Maingon, P., Rolland, F., Bolla, M., Cognetti, F., Bourhis, J., Kirkpatrick, A. and van Glabbeke, M.: Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer. *New Eng J Med*, 350 (19):1945-1952, 2004.

continued on next page

Bourhis, J., Amand, C. and Pignon, J.-P.: Update of MACH-NC (Meta-Analysis of Chemotherapy In Head & Neck Cancer) Database Focused on Concomitant Chemotherapy. Proc Am Soc Clin Oncol (ASCO), New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. 488, Abs. #5505, 2004.

Cooper, J., Pajak, T., Forastiere, A., Jacobs, J., Campbell, B., Saxman, S., Kish, J., Kim, H., Cmelak, A., Rotman, M., Machtay, M., Ensley, J., Chao, C., Schultz, C., Lee, N. and Fu, K.: Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck. *New Eng J Med*, 350 (19):1937-1944, 2004.

Konski, A., Pajak, T., Movsas, B., Coyne, J., Harris, J., Gwede, C., Garden, A., Spencer, S., Jones, C. and Watkins Bruner, D.: Socio-Demographic Variables Influence Outcome in Radiation Therapy Oncology Group Head and Neck Trials. Proc Am Soc Clin Oncol (ASCO), New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. 527, Abs. #6043, 2004.

Kumar, P., Harris, J., Garden, A., Fu, K., Robbins, K. T., Pajak, T. and Ang, K. K.: Outcome Comparisons of Four Radiation Therapy Oncology Group (RTOG) Trials in Patients with Stage IV-T4 Head and Neck (H/N) Cancer: Encouraging Results Using Intra-Arterial (IA) Cisplatin (P) and Radiation Therapy (RT). Proc Am Soc Clin Oncol (ASCO), New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. 493, Abs. #5527, 2004.

Langer, C., Harris, J., Horwitz, E., Nicolaou, N., Kies, M., Curran Jr, W., Wong, S. and Ang, K. K.: Phase II Trial Of Concurrent Split Course Hyperfractionated Radiotherapy (Hfx RT), Cisplatin (DDP) and Paclitaxel (P) in Patients with Recurrent, Previously Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN): Results of RTOG 9911. Proc Am Soc Clin Oncol (ASCO), New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. 488, Abs. #5509, 2004.

Trotti, A., Garden, A., Warde, P., Symonds, P., Langer, C., Redman, R., Pajak, T., Fleming, T., Henke, M., Bourhis, J., Rosenthal, D., Junor, E., Cmelak, A., Sheehan, F., Pulliam, J., Risse, P., Fuchs, H., Chambers, M., O'Sullivan, B. and Ang, K. K.: A Multinational, Randomized Phase III Trial of Isegran HCL Oral Solution for Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head-and-Neck Malignancy. *Int J Radiat Onco Biol Phys*, 58 (3):674-681, 2004.

LUNG CANCER

Strauss, G., Herndon II, J. E., Maddaus, M., Johnstone, D., Johnson, E., Watson, D., Sugarbaker, D., Schilsky, R. and Green, M.: Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc Am Soc Clin Oncol (ASCO), New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. Abs. #7019, 2004.

PROSTATE CANCER

Konski, A., Watkins-Bruner, D., Brereton, H. and Hanks, G.: Long-Term Hormone Therapy in addition to Radiation is Cost-Effective in the Treatment of Patients with Locally Advanced Prostate Cancer: An Economic Analysis of Radiation Therapy Oncology Group (RTOG) protocol 92-02. Amer Radium Society (ARS), Napa Valley, CA, *Proceedings from ARS Booklet*, pg. 25, Abs. #24, 2004.

Lee, W., DeSilvio, M., Lawton, C., Gillin, M., Morton, G., Firat, S., Baikadi, M., Kuettel, M., Greven, K. and Sandler, H.: A Phase II Study of External Beam Radiation Therapy Combined With Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate: Preliminary Results of RTOG P-0019. Proc Am Soc Clin Oncol (ASCO), New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. 397, Abs. #4568, 2004.

Michalski, J., Winter, K., Purdy, J., Perez, C., Ryu, J., Parliament, M., Valicenti, R., Roach III, M., Sandler, H., Markoe, A. and Cox, J.: Toxicity After Three-Dimensional Radiotherapy for Prostate Cancer with RTOG 9406 Dose Level IV. *Int J Radiat Onco Biol Phys*, 58 (3):735-742, 2004.

Pollack, A., DeSilvio, M., Khor, L., Al-Saleem, T., Hammond, E., Li, R., Roach III, M., SA, R., Movsas, B., Shipley, W., Hanks, G. and Sandler, H.: Recursive Partitioning Analysis of Predictors of Distant Metastasis for Men with Prostate Cancer Treated with Radiotherapy and Androgen Deprivation on RTOG 9202: The Impact of Ki-67. Amer Urology Assoc (AUA), San Francisco, CA, *J of Urology*, (May 8-13, 2004) pg. Abs. #597, 2004.

Pollack, A., DeSilvio, M., Khor, L., Li, R., Al-Saleem, T., Hammond, E., Venkatesan, V., Lawton, C., Roach III, M., Shipley, W., Hanks, G. and Sandler, H.: Ki-67 Staining is a Strong Predictor of Distant Metastasis and Mortality for Men with Prostate Cancer Treated with Radiotherapy Plus Androgen Deprivation: Radiation Therapy Oncology Group Trial 92-02. *J Clin Oncol*, 22 (11):2133-2140, 2004.

OUTCOMES RESEARCH

Konski, A. and Watkins-Bruner, D.: The RTOG Outcomes Model: Economic Endpoints and Measures. Expert Opin *Pharmacoeconomics*, 5 (3):513-519, 2004.

Watkins-Bruner, D., Movsas, B., Konski, A., Roach III, M., Bondy, M., Scarantino, C., Scott, C. and Curran Jr, W.: Outcomes Research in Cancer Clinical Trial Cooperative Groups: The RTOG Model. *Quality of Life Research*, 13 (6):1025-1041, 2004.

MISCELLANEOUS

Coyne, J., Pajak, T., Harris, J., Konski, A., Movsas, B., Ang, K. K. and Watkins-Bruner, D.: Depressed Mood and Survival Among Patients with Head and Neck Cancer. Am Psychosomatic Soc, Orlando, FL, *Proceedings from Am Psychosomatic Bklt*, [March, 2004] pg. 11, Abs. #1566, 2004.

Malyapa, R.: Oncologic Imaging of Tumor Hypoxia and Correlating Findings on Cu-ATSM PET Scans to Cellular Markers That May Predict for Radiation Response. RTOG Semi-Annual Meeting, New Orleans, LA, Simon Kramer New Investigator Award, pg. 1, Abs. #1, 2004.

Soares, H., Daniels, S., Kumar, A., Clarke, M., Scott, C., Swann, S. and Djulbegovic, B.: Bad Reporting Does Not Mean Bad Methods For Randomized Trials: Observational Study Of Randomized Controlled Trials Performed By The Radiation Therapy Oncology Group. *British Medical Journal*, 328 (1):22-25, 2004.

Soares, H., Kumar, A., Daniels, S., Sargent, D., Buckner, J., Swann, S., Smith, R., Khyayat, A., Wells, R. and Djulbegovic, B.: Lack of Publication Bias in Randomized Clinical Trials (RCTs) Sponsored by the National Cancer Institute (NCI) and Performed by Cooperative Oncology Groups (COGs). Proc Am Soc Clin Oncol (ASCO), New Orleans, LA, *J Clin Oncol*, [23] (June 5-8, 2004) pg. 518, Abs. #6004, 2004.

Trotti, A., Gwede, C., Pajak, T., Paulus, R. and Saranga, S.: The TAME Summary Reporting and Risk Classification System for Comparing Treatment Options in Oncology. LENT V Workshop, Rochester, NY, *LENT V Meeting Booklet*, pg. Session 4, Abs. #1, 2004.

Young, B., Welsh-Motyka, E., Swann, S. and King, S.: Developing Metrics For Cooperative Clinical Trials Group Data Management and Statistical Center. Soc Clinical Trials, New Orleans, LA, *Controlled Clin Trials*, [1] (2) pg. 247, Abs. #P35, 2004.

TRANSLATIONAL RESEARCH PUBLICATIONS FROM JUNE 2003 RTOG SYMPOSIUM

Ang, K. K., Andratschke, N. H. and Milas, L.: Epidermal Growth Factor Receptor and Response of Head-and-Neck Carcinoma to Therapy. *Int J Radiat Onco Biol Phys*, 58 (3):959-965, 2004.

Bonner, J., Buchsbaum, D., Rogers, B., Grizzle, W., Trummell, H., Curiel, D., Fiveash, J., Ove, R. and Raisch, K.: Adenoviral Vector-Mediated Augmentation of Epidermal Growth Factor Receptor (EGFr) Enhances the Radiosensitization Properties of Anti-EGFr Treatment in Prostate Cancer Cells. *Int J Radiat Onco Biol Phys*, 58 (3):950-958, 2004.

continued on next page

RTOG Top Accruing Institutions *as of August 31, 2004*

Full Members

1. University of Texas-MD Anderson Cancer Ctr.	49
2. Notre Dame Hospital/University of Montreal	43
3. Cleveland Clinic Foundation	39
4. Tom Baker Cancer Centre	37
5. McGill University	34
6. Radiological Associates of Sacramento	33
7. Cross Cancer Institute - University of Alberta	30
8. University of Western Ontario	30
9. McMaster University, Hamilton	27
10. Akron City Hospital	26
11. Foundation for Cancer Research and Education	24
12. Dartmouth Hitchcock Medical Center	23
12. Wayne State University	23
14. Thomas Jefferson University Hospital	20
15. Harvard Radiation Oncology Program	19
15. Roswell Park Cancer Institute	19
15. University of Rochester	19
18. Fox Chase Cancer Center	18
19. Mayo Clinic	17
19. SUNY Health Science Center/Brooklyn	17

Affiliate Members

1. University of Colorado Health Sciences Center	25
2. Toronto-Sunnybrook Regional Cancer Centre	20
3. L'Hotel-Dieu de Quebec	15
4. University of Wisconsin Hospital	13
5. Zablocki VA Medical Center-Wood	13
6. Princess Margaret Hospital	12
7. Univ. of Florida, College of Med. at Shands	11
8. Mt. Diablo Medical Center	11
9. Nova Scotia Cancer Centre	11
10. Akron General Medical Center	10
10. Methodist Cancer Center	10
10. University of Miami	10

CCOP Members

1. Mt. Sinai Comprehensive Cancer Center CCOP	35
2. Metro-MN CCOP	34
3. Christiana Care Health Services, Inc.	25
4. Southeast Cancer Control Consortium, Inc.,	21
5. LIMR/MLH CCOP	14
6. Cancer Research for the Ozarks	13
6. Michigan Cancer Research Consortium CCOP	13
8. Greenville S.C. CCOP	12
9. St. Vincent Regional Cancer Center CCOP	11
10. Kansas City CCOP	10

RTOG Semi-Annual Meeting

January 20 - 23, 2005

*Sheraton Wild Horse Pass Resort,
Phoenix, AZ*

RTOG Publications January - August 2004 *continued from page 10*

Chakravarti, A., Dicker, A. and Mehta, M.: The Contribution of Epidermal Growth Factor Receptor (EGFR) Signaling Pathway To Radioresistance in Human Gliomas: A Review of Preclinical and Correlative Clinical Data. *Int J Radiat Onco Biol Phys*, 58 (3):927-931, 2004.

Dancey, J.: Epidermal Growth Factor Receptor Inhibitors in Clinical Development. *Int J Radiat Onco Biol Phys*, 58 (3):1003-1007, 2004.

Dicker, A. and Rodeck, U.: Targeting the EGFR in Neoplasia — More Questions Than Answers. *Int J Radiat Onco Biol Phys*, 58 (3):899-902, 2004.

Dicker, A.: Foreword: Epidermal Growth Factor Receptor (EGFR) Inhibitors and Cancer Therapeutics. *Int J Radiat Onco Biol Phys*, 58 (3):898, 2004.

Foon, K., Yang, X., Weiner, L., Beldegrun, A., Figlin, R., Crawford, J., Rowinsky, E., Dutcher, J., Vogelzang, N., Gollub, J., Thompson, J., Schwartz, G., Bukowski, R., Roskos, L. and Schwab, G.: Preclinical and Clinical Evaluations of ABX-EGF, A Fully Human Anti-Epidermal Growth Factor Receptor Antibody. *Int J Radiat Onco Biol Phys*, 58 (3):984-990, 2004.

Harari, P. and Huang, S. M.: Combining EGFR Inhibitors With Radiation Or Chemotherapy: Will Preclinical Studies Predict Clinical Results? *Int J Radiat Onco Biol Phys*, 58 (3):976-983, 2004.

Langer, C.: Emerging Role of Epidermal Growth Factor Receptor Inhibition in Therapy for Advanced Malignancy: Focus on NSCLC. *Int J Radiat Onco Biol Phys*, 58 (3):991-1002, 2004.

Marmor, M. D., Skaria, K. and Yarden, Y.: Signal Transduction and Oncogenesis by ErbB/HER Receptors. *Int J Radiat Onco Biol Phys*, 58 (3):903-913, 2004.

Mass, R. D.: The HER Receptor Family: A Rich Target For Therapeutic Development. *Int J Radiat Onco Biol Phys*, 58 (3):932-940, 2004.

Milas, L., Fan, Z., Andratschke, N. H. and Ang, K. K.: Epidermal Growth Factor Receptor and Tumor Response to Radiation: In Vivo Preclinical Studies. *Int J Radiat Onco Biol Phys*, 58 (3):966-971, 2004.

Ochs, J. S.: Rationale and Clinical Basis for Combining Gefitinib (IRESSA, ZD1839) with Radiation Therapy for Solid Tumors. *Int J Radiat Onco Biol Phys*, 58 (3):941-949, 2004.

Quang, T. S. and Brady, L.: Radioimmunotherapy as a Novel Treatment Regimen: 125I-Labeled Monoclonal Antibody 425 in the Treatment of High-Grade Brain Gliomas. *Int J Radiat Onco Biol Phys*, 58 (3):972-975, 2004.

Viloria-Petit, A. and Kerbel, R.: Acquired Resistance to EGFR Inhibitors: Mechanisms and Prevention Strategies. *Int J Radiat Onco Biol Phys*, 58 (3):914-926, 2004.

January 2005 Symposium

PSA

watch for more information



Listed below is the active protocol list as of August 31, 2004. This can be cut out and folded to fit in a wallet or pocket. Please photocopy and distribute to your colleagues so they can also participate in RTOG protocols.

BRAIN TUMORS

9813 Anaplastic Astro I/III Chem, RT, Tem
 0227* CNS Lymphoma I/II Chem, RT

BREAST CANCER

9804** DCIS III RT

CANCER CONTROL

0122 Cancer Cachexia CC Juven
 0123 NSCLC/SCLC CC Captopril
 0127 NSCLC (I-II) CC Selenium
 0215 Erectile Dysfunction CC Sildenafil
 0315 Sandos vs Placebo CC Sandos

GASTROINTESTINAL CANCER

9811 Anal Canal CA III Chem, RT
 0113 Esophageal CA IIR Chem, RT
 0246 Esophageal CA II Chem, Surg
 0247 Resectable Rectal IIR RT & Surg & Chemo

GENITOURINARY CANCER

9902* Prostate CA III Chem, Horm, RT
 0014** Prostate CA III Horm, Chemo
 0126 Prostate CA III 3D-CRT/IMRT
 0232 Prostate CA III RT, Brachy
 0233 Bladder CA IIR Surg, Chem, RT
 0321 Prostate CA II RT, Brachy

GYNECOLOGIC CANCER

0116 Cervix, Pos. Nodes I/II Celeb, Chem, RT

HEAD & NECK CANCER

0022 Oropharyngeal CA I/II IMRT
 0129 Advanced III Chem, RT
 0225 Nasopharynx II IMRT, Chem
 0234 Advanced IIR RT, Chemo
 0244 Salivary Gland II Surg, RT

LUNG CANCER

0015 NSCLC (IB-III A) III Chem, Surg
 0017* NSCLC (IIA/B) I Chem, RT
 0117 NSCLC (I-III B) I/II 3D, Chem
 0212 SCLC II/III PCI
 0213* NSCLC I/II Celebex, RT
 0214** NSCLC (IIIA & IIIB) III PCI
 0236 NSCL (Stage I/II) II Sterotatic RT
 0239 SCLC II RT, Chem
 0241* SCLC I Irinotecan, RT
 0324 NSCLC II C225, RT, Chem

SARCOMA

0132 GI Tumors II Surg, STI-571
 0330 Sarcoma II RT, Chemo, Surg

* Study temporarily closed

** On CTSU Endorsed Study Menu

RTOG Randomization Desk Hours

8:30 am - 5:00 pm EST
 (except for dates below)

215.574.3191 FAX: 215.574.0300

Friday, September 3	8:30 AM – 3:00 PM	
Monday, September 6	Closed	Labor Day
Wednesday, November 24	8:30 AM – 3:00 PM	
Thursday, November 25	Closed	Thanksgiving
Friday, November 26	Closed	
Thursday, December 23	8:30 AM – 3:00 PM	
Friday, December 24	Closed	Christmas Eve
Thursday, December 30	8:30 AM – 3:00 PM	
Friday, December 31	Closed	New Year

NOTE: Patient registration is available via the internet 24 hours a day, seven days a week.

Future Meeting Dates

January 20 - 23, 2005

Sheraton Wild Horse Pass Resort, Phoenix

June 23 - 26, 2005

Loews Philadelphia Hotel, Philadelphia

January 19 - 22, 2006

Fontainebleau Hilton Resort, Miami Beach

June 22 - 25, 2006

Fairmont Royal York, Toronto, Ontario

February 1 - 4, 2007

Tampa Marriott Waterside Hotel, Tampa

June 21 - 24, 2007

Loews Philadelphia Hotel, Philadelphia